<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01809912</url>
  </required_header>
  <id_info>
    <org_study_id>MG1102_001</org_study_id>
    <nct_id>NCT01809912</nct_id>
  </id_info>
  <brief_title>Safety Study of MG1102 in Patients With Solid Tumors</brief_title>
  <official_title>A PHASE 1, OPEN LABEL, DOSE ESCALATION STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF MG1102 IN PATIENTS WITH SOLID TUMORS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Green Cross Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ICON Clinical Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Green Cross Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the safety and tolerability of a 28 day course of intravenous (IV) MG1102 in&#xD;
      patients with solid tumors for which no standard therapy is available.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, Dose Escalation Study, multicenter phase I study to evaluate the&#xD;
      safety and tolerability, determine the pharmacokinetics, and obtain preliminary information&#xD;
      regarding pharmacodynamics and efficacy of MG1102 in subjects with solid tumor.&#xD;
&#xD;
      Each subject will receive on dose of MG1102 followed by a 6-day rest period. If the initial&#xD;
      dose is tolerated, subject will continue with the 21 days of MG1102 administration (5 days on&#xD;
      treatment, 2 days off treatment for 3 weeks.) Subjects that have a tumor response as stable&#xD;
      disease, may continue therapy on a compassionate use.&#xD;
&#xD;
      Study Duration : for a minimum of 8 weeks&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To investigate the safety and tolerability IV MG1102</measure>
    <time_frame>A minimum of 9 weeks</time_frame>
    <description>Adverse events, physical examinations, vital signs, ECGs, clinical laboratory evaluations, lipid profiles</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Each subject's serum drug concentration-time data to determine the pharmacokinetic profile of MG1102</measure>
    <time_frame>for 25 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>standard clinical serum tumor markers via serum samples to obtain preliminary information regarding the pharmacodynamics of MG1102</measure>
    <time_frame>A minimum of 10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of response assessed by RECIST v1.1 and Choi criteria to obtain preliminary information regarding the efficacy of MG1102</measure>
    <time_frame>A minimum of 11 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Greenstatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1 : 6 mg/m2 Cohort 2 : 12 mg/m2 Cohort 3 : 24 mg/m2 Cohort 4 : 48 mg/m2 Cohort 5 : 96 mg/m2 Cohort 6 : 192 mg/m2 28 Day Course Subjects will receive MG1102 (Recombinant human apolipoprotein(a) Kringle V ) by IV administration on Day 0. If no DLTs are observed during the 6 days following the initial infusion, the same dose will be administered once daily for 5 consecutive days followed by a 2-day rest period three times (over 21 days), completing the course on Day 27.&#xD;
Additional 21 Day Courses In the absence of a DLT, and in the case of stable disease or better, a subject may continue to receive MG1102 (Recombinant human apolipoprotein(a) Kringle V&#xD;
) on a compassionate use basis at the same dose and regimen .</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant human apolipoprotein(a) Kringle V</intervention_name>
    <arm_group_label>Greenstatin</arm_group_label>
    <other_name>Greenstatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years of age or older&#xD;
&#xD;
          -  Solid tumors refractory to conventional therapy or the subject does not tolerate the&#xD;
             conventional therapy&#xD;
&#xD;
          -  Evaluable disease or at least one measurable tumor mass by a radiographic technique&#xD;
&#xD;
          -  Life expectancy ≥3 months&#xD;
&#xD;
          -  Suitable for intravenous administration of study medication&#xD;
&#xD;
          -  Signed written informed consent&#xD;
&#xD;
          -  Adequate bone marrow, renal, and liver function&#xD;
&#xD;
          -  Coagulation profile with aPTT and INR, each ≤ 1.5 x ULN&#xD;
&#xD;
          -  No evidence of active Hepatitis B or Hepatitis C infection&#xD;
&#xD;
          -  Proteinuria &lt;100 mg&#xD;
&#xD;
          -  ECOG performance status ≤2&#xD;
&#xD;
          -  Female subjects must agree to use contraceptive measures&#xD;
&#xD;
          -  Negative serum ß-hCG&#xD;
&#xD;
          -  Ability and willingness to comply with the study protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Therapy with systemic anticoagulant or antithrombotic agentswithin 7 days prior to&#xD;
             first dose&#xD;
&#xD;
          -  Hemoptysis within 3 months prior to first dose&#xD;
&#xD;
          -  Cytotoxic chemotherapy, immunotherapy, or radiotherapy within 4 weeks prior to first&#xD;
             dose&#xD;
&#xD;
          -  Surgery or visceral biopsy within 28 days prior to first dose&#xD;
&#xD;
          -  Minor surgical procedure performed within 7 days prior to first dose&#xD;
&#xD;
          -  Prior exposure to MG1102&#xD;
&#xD;
          -  Known history of HIV&#xD;
&#xD;
          -  With active bacterial infections and/or receiving systemic antibiotics&#xD;
&#xD;
          -  Current or past diagnosis of leukemia&#xD;
&#xD;
          -  Known CNS metastases or clinical evidence of CNS&#xD;
&#xD;
          -  Non-healing wound within past 2 weeks&#xD;
&#xD;
          -  Bleeding diathesis or bleeding within 14 days prior to enrollment&#xD;
&#xD;
          -  Clinically significant thrombosis&#xD;
&#xD;
          -  Non-malignant GI bleeding, gastric stress ulcerations, or peptic ulcer disease&#xD;
&#xD;
          -  History of idiopathic or hereditary angioedema&#xD;
&#xD;
          -  History of sickle cell or any hemolytic anemia&#xD;
&#xD;
          -  Require hemoglobin, WBC, or platelet transfusion support or use of hematopoietic&#xD;
             growth factors within 2 weeks prior to entry&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  History of clinically significant renal disease&#xD;
&#xD;
          -  History of significant medical illness of cardiac or CNS disease within the past 6&#xD;
             months&#xD;
&#xD;
          -  Treatment with an investigational agent within the longest time frame of either 5&#xD;
             half-lives or 30 days of initiating study drug&#xD;
&#xD;
          -  Medical or psychiatric illness&#xD;
&#xD;
          -  Recreational substance use or psychiatric illness&#xD;
&#xD;
          -  Known hypersensitivity to MG1102 or components of the formulation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>hyunchul chung, dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yonsei Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yonsei Cancer Center, Yonsei University Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <study_first_submitted>October 30, 2012</study_first_submitted>
  <study_first_submitted_qc>March 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2013</study_first_posted>
  <last_update_submitted>November 25, 2015</last_update_submitted>
  <last_update_submitted_qc>November 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>solid tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

